Medicaid Pharmacy and Therapeutics Committee Agenda for February 26, 2009

The Pharmacy & Therapeutics Committee will meet February 26, 2009, from 8:45 a.m. to 3:45 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York

Agenda:

1. Review of the Topical Antibiotic therapeutic class for inclusion to the Preferred Drug Program.

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drug(s ) Affected: Altabax (retapamulin), Bactroban (mupirocin), mupirocin.

2. Review of the Topical Anti-Viral therapeutic class for inclusion to the Preferred Drug Program.

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drug(s) Affected: Abreva (docosanol), Denavir (penciclovir), Zovirax (acyclovir).

3. Review of the Topical Psoriasis therapeutic class for inclusion to the Preferred Drug Program.

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drug(s) Affected: calcipotriene, Dovonex (calcipotriene), Psoriatec (anthralin), Taclonex (calcipotriene/betamethasone dipropionate).

4. Review of the Nasal Antihistamine therapeutic class for inclusion to the Preferred Drug Program.

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drug(s) Affected: Astelin (azelastine), Astepro (azelastine), Patanase (olopatadine)

5. Review of the Non-Ergot Dopamine Receptor Agonist therapeutic class for inclusion to the Preferred Drug Program

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drug(s) Affected: Requip (ropinirole), Requip XL (ropinirole ER) Mirapex (pramipexole), ropinirole.

6. Review of the Direct Renin Inhibitor therapeutic class for inclusion to the Preferred Drug Program

Description: The Committee will review the therapeutic class to determine whether the class should be included in the Preferred Drug Program.

Drug(s) Affected: Tekturna (aliskiren), Tekturna HCT (aliskiren/HCTZ).

7. Review of the Skeletal Muscle Relaxant therapeutic class for inclusion to the Preferred Drug Program.

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drug(s) Affected: Amrix (cyclobenzaprine ER), baclofen, carisoprodol, carisoprodol compound, carisoprodol compound-codeine, chlorzoxazone, cyclobenzaprine, Dantrium (dantrolene), dantrolene, Fexmid (cyclobenzaprine), methocarbamol, orphenadrine, orphenadrine compound, orphenadrine compound forte, Parafon Forte DSC (chlorzoxazone), Robaxin (methocarbamol), Skelaxin (metaxalone), Soma (carisoprodol), Soma compound (carisoprodol compound), Soma compound-codeine (carisoprodol compound-codeine), tizanidine, Zanaflex (tizanidine).

8. Review of the Prescription Non-Steroidal Anti-Inflammatory therapeutic class for inclusion to the Preferred Drug Program.

Description: The Committee will review the following drugs to determine preferred and non-preferred status.

Drug(s) Affected: Anaprox (naproxen sodium), Anaprox DS (naproxen sodium DS) Arthrotec (diclofenac sodium/misoprostol), Cataflam (diclofenac potassium), Clinoril (sulindac), Daypro (oxaprozin), diclofenac potassium, diclofenac sodium, diclofenac sodium XR, diflunisal, etodolac, etodolac SA, Feldene (piroxicam), fenoprofen, Flector (diclofenac epolamine), flurbiprofen, ibuprofen, Indocin (indomethacin), indomethacin, indomethacin SR, ketoprofen, ketoprofen SA, ketorolac, Mobic (meloxicam), meclofenamate, mefenamic acid, meloxicam, nabumetone, Nalfon (fenoprofen), Naprelan (naproxen sodium CR), Naprosyn (naproxen), naproxen, naproxen sodium, naproxen EC, oxaprozin, piroxicam, Ponstel (mefenamic acid), sulindac, tolmetin, Voltaren (diclofenac sodium), Voltaren XR (diclofenac sodium DR), Voltaren Gel (diclofenac sodium).

Agenda Timeline (subject to change based on meeting proceedings):

Time Agenda Topic
8:45 - 9:00 Welcome and Introductions
9:00 - 10:00 Public Comments from interested parties*
10:00 - 10:15 Break
10:15 - 11:45 Review of Topical Antibiotics, Topical Anti-Virals, Topical Psoriasis Agents, Nasal Antihistamines
11:45 - 12:45 Executive Session/Lunch Break
12:45 - 1:00 Summary of Recommendations
1:00 - 2:15 Review of Non-Ergot Dopamine Receptor Agonists, Direct Renin Inhibitors, Skeletal Muscle Relaxants, NSAIDs
2:15 - 3:15 Executive Session
3:15 - 3:30 Summary of Recommendations
3:30 - 3:45 DOH Update, Final Comments and Adjournment

* Interested parties must notify DOH at least 1 week in advance of their request to speak during the public comment period. Requests may be made by calling 518-486-3209 or e-mailing ppno@health.state.ny.us (please reference P&T Committee). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total public comment period will not exceed one (1) hour. All written comments regarding topics before the Committee must be received electronically at least 1 week in advance of the meeting. Written comments should summarize key points and may not exceed two (2) pages in length.

NOTE: Those wishing to submit clinical studies or clinical reports, rather than comments, must submit the study/report electronically at least two weeks prior to the date of the meeting in order to allow sufficient time for the Committee to review this type of material.

Posted January 27, 2009